-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

621.P1.23 621. Hodgkin Lymphoma: Biology, excluding Therapy: Poster I

Hodgkin Lymphoma: Biology, excluding Therapy Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 5, 2015: 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Ralph Schwiebert, MBBS1*, Sharon Barrans, PhD2*, Jan Taylor3*, Andrew S Jack1 and Cathy H Burton1*

1HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
2St James Institute of Oncology, HMDS, Leeds, United Kingdom
3HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Jose Villasboas Bisneto, M.D.1 and Stephen M Ansell, M.D., Ph.D.2

1Division of Hematology - Department of Medicine, Mayo Clinic, Rochester, MN
2Division of Hematology, Mayo Clinic, Rochester, MN

Fazlyn Reeny Abdul Razak*, Arjan Diepstra, MD, PhD, Lydia Visser, PhD* and Anke Van den Berg, PhD

Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Christopher Daniel Carey, M.D.,1*, Courtney Connelly2*, Evisa Gjini, PhD1, Margaretha GM Roemer, MS2*, Edward Stack, PhD3*, Stephen Hodi, MD2*, Margaret A. Shipp, MD2 and Scott J. Rodig, M.D., Ph.D.4

1Department of Pathology, Brigham & Women's Hospital, Boston, MA
2Dana-Farber Cancer Institute, Boston, MA
3PerkinElmer, Hopkington, MA
4Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

Tarsheen K. Sethi, MD, MS1, Van T Nguyen, MD2*, Shaoying Li, MD3*, David S Morgan, MD4, John P. Greer, MD4 and Nishitha M Reddy, M.B.B.S.4

1Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
2Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
3Department of Hematopathology, MD Anderson Cancer Center, Houston, TX
4Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

Sara Alonso, MD1*, Maria Belen Vidriales, MD, PhD1*, Maria Dolores Caballero, MD, PhD2*, Oscar Blanco3*, J Galende4*, Maria Jesús Peñarrubia, MD, PhD5*, Esther Zato5*, Abelardo Barez6*, Julio Davila6*, Juan Carlos Caballero, MD7*, Alberto Orfao, MD, PhD8, Marcos González, MD, PhD9* and Ramon Garcia-Sanz, MD, PhD10*

1Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
2Universitiy Hospital of Salamanca, Universitiy Hospital of Salamanca, Salamanca, Spain
3Pathology Department, University Hospital of Salamanca, Salamanca, Spain
4Virgen del Bierzo Hospital, Ponferrada, Spain
5Clinical Hospital of Valladolid, Valladolid, Spain
6University Hospital of Salamanca, Salamanca, Spain
7Hematology, Salamanca Universitary Hospital, Salamanca, Spain
8Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC), Servicio General de Citometría, Universidad de Salamanca, Salamanca, Spain
9Hospital Clínico Universitario de Salamanca, Salamanca, Spain
10Hematology Service, University Hospital of Salamanca, Salamanca, Spain

*signifies non-member of ASH